Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

Stopped early · Phase 4

Conditions studied: Soft Tissue Infections

In brief

This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.

Key facts

Study ID

NCT00102947

Run by

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

People needed

72

Starts

2005-01-01

Expected to finish

2006-11-01

Last updated by the study team

2016-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Harbor UCLA Medical Center — Torrance, California, United States
• Tampa General Hospital — Tampa, Florida, United States
• Joseph M. Still Research Institute — Augusta, Georgia, United States
• Infectious Diseases Minneapolis-LTD — Minneapolis, Minnesota, United States
• Upstate Clinical Research Associates — Buffalo, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• AllTrials Clinical Research — Winston-Salem, North Carolina, United States
• Riverside Methodist Hospital — Columbus, Ohio, United States
• Wright State University/Veterans Affairs Medical Center — Dayton, Ohio, United States
• ID Clinical Research — Toledo, Ohio, United States
• St. Luke's Hospital — Bethlehem, Pennsylvania, United States
• The Reading Hospital and Medical Center — West Reading, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.